Paper
13 July 1999 Preliminary investigation into the use of diffuse optical tomography for monitoring and imaging stroke
David A. Boas, Thomas J. Gaudette, Lai Wang, Hakan Ay, Walter Koroshetz, Gregory Sorensen M.D.
Author Affiliations +
Abstract
For patients with ischemic stroke there is benefit to early treatment (within 3 hours) with recombinant tissue plasminogen activator, rt-PA, an FDA approved thrombolytic drug. The use of rt-PA within the first 3 hours of an ischemic stroke is based upon a clinical trial showing an increased probability of good functional recovery in the treated group. The challenge is now to individualize therapy in order to decrease the degree of permanent brain injury due to ischemia in as many patients as possible. This requires new tools to assay brian flood flow and tissue injury. However, there is currently no means to non-invasively monitor brain perfusion. There is no non-invasive method to determine whether administration of thrombolytic drug in an individual patient is actually effective in causing reperfusion. We have developed such a method based on using light in conjunction with periodic bolus injections of an optical vascular contrast agent to continuously monitor brain perfusion non-invasively.
© (1999) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
David A. Boas, Thomas J. Gaudette, Lai Wang, Hakan Ay, Walter Koroshetz, and Gregory Sorensen M.D. "Preliminary investigation into the use of diffuse optical tomography for monitoring and imaging stroke", Proc. SPIE 3712, Battlefield Biomedical Technologies, (13 July 1999); https://doi.org/10.1117/12.353023
Lens.org Logo
CITATIONS
Cited by 1 scholarly publication.
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Brain

Tissue optics

Sensors

Diffuse optical tomography

Indocyanine green

Ischemic stroke

Blood

Back to Top